65 Quai Georges Gorse
Cedex
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 4,500
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David Loew | MD, CEO & Director | 2.5M | N/A | 1967 |
Mr. Aymeric Le Chatelier | Exec. VP & Group CFO | N/A | N/A | 1969 |
Dr. Aidan Murphy Ph.D. | Exec. VP of Technical Operations | N/A | N/A | 1966 |
Mr. Craig Marks | Vice-Pres of Investor Relations | N/A | N/A | N/A |
Mr. Francois Garnier | Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer | N/A | N/A | 1962 |
Ms. Gwenan White | Exec. VP of Communications & Public Affairs | N/A | N/A | N/A |
Mr. Regis Mulot | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
Mr. Stephan Gagne | Head of New Tokyo Office | N/A | N/A | N/A |
Ms. Dominique Bery | Head of Nordics & Baltics | N/A | N/A | 1971 |
Dr. Yan Moore M.D. | Sr. VP & Head of Oncology Therapeutic Area | N/A | N/A | 1967 |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Ipsen S.A.’s ISS governance QualityScore as of 28 January 2023 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 7; Compensation: 7.